Quantitative Detection of ID4 Gene Aberrant Methylation in the Differentiation of Myelodysplastic Syndrome from Aplastic Anemia.
- Author:
Mian-Yang LI
;
Yuan-Yuan XU
;
Hui-Yuan KANG
;
Xin-Rong WANG
;
Li GAO
;
Jian CEN
;
Wei WANG
;
Nan WANG
;
Yong-Hui LI
;
Li-Li WANG
;
Li YU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; genetics; Child; CpG Islands; genetics; DNA Methylation; genetics; Female; Humans; Inhibitor of Differentiation Proteins; genetics; Male; Middle Aged; Myelodysplastic Syndromes; genetics; Young Adult
- From: Chinese Medical Journal 2015;128(15):2019-2025
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDThe diagnosis of myelodysplastic syndrome (MDS), especially hypoplastic MDS, and MDS with low blast counts or normal karyotype may be problematic. This study characterized ID4 gene methylation in patients with MDS and aplastic anemia (AA).
METHODSThe methylation status of ID4 was analyzed by bisulfite sequencing polymerase chain reaction (PCR) and quantitative real-time methylation-specific PCR (MethyLight PCR) in 100 patients with MDS and 31 patients with AA.
RESULTSThe MDS group had a higher ID4 gene methylation positivity rate (22.22%) and higher methylation levels (0.21 [0-3.79]) than the AA group (P < 0.05). Furthermore, there were significant differences between the hypoplastic MDS and AA groups, the MDS with low blast count and the AA groups, and the MDS with normal karyotype and the AA groups. The combination of genetic and epigenetic markers was used in much more patients with MDS (62.5% [35/56]) than the use of genetic markers only (51.79% [29/56]).
CONCLUSIONSThese results showed that the detection of ID4 methylation positivity rates and levels could be a useful biomarker for MDS diagnosis.
